Evidence map›Paper›PMID 41290309›Full record

ArticleBMJ open2025

Stiefel MD Anderson OroPharynx cancer (MDA-OPC) cohort: a single-institution, prospective longitudinal outcomes study.

Amy Moreno, Ariana J Sahli, Faye Johnson, Xiaowen Sun, Carly Barbon, Waree Rinsurongkawong, Wenye Song, Flavie M Luciani, Han Liang, Jun Li and 7 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01893307 phase3active not recruitingnot on this map

Phase III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2013 to 2031Enrolled440ConditionsStage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7ArmsIntensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
NCT03145077 narecruitingnot on this map

Using Magnetic Resonance Imaging (MRI) to Assess Mandibular and Soft Tissue Responses to Radiation Therapy

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2017 to 2027Enrolled1,400ConditionsHead and Neck CancerArmsDynamic Contrast-Enhanced Magnetic Resonance Imaging, Questionnaire Administration
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Amy MorenoRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA AKMoreno@mdanderson.org.ORCID http://orcid.org/0000-0001-6762-6807
Ariana J SahliHead and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Faye JohnsonThoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xiaowen SunBiostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Carly BarbonHead and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Waree RinsurongkawongBiostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wenye SongHead and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Flavie M LucianiHead and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Han LiangBioinformatics and Computational Biology; Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jun LiBioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wei LiuBioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0001-9881-785X
J Jack LeeBiostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
S J FrankRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Stephen LaiHead and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Clifton FullerRadiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Katherine HutchesonHead and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0003-3710-5706
P01 MD Anderson Oropharynx Cancer Program

Funding

Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
Project 3: OPC-RADP01CA285249 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Clifton David Fuller, Katherine Arnold Hutcheson · 2024 to 2026
$9.4M
Provider and Patient-generated Remote Oro-Dental Health Electronic Data Capture for Algorithmic Longitudinal Evaluation and Risk-Assessment (PROHEALER)K01DE030524 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MORENO, AMY CATHERINE · 2022 to 2024
$479k
NCI NIH HHS K12 CA088084NCI NIH HHS P01 CA285249NIDCR NIH HHS K01 DE030524
6 · The paper itself

Abstract

purposeThe MD Anderson Oropharynx Cancer (MDA-OPC) cohort is a unique single-institution, prospective longitudinal cancer cohort. The cohort aims to enhance the therapeutic index of OPC management by supporting data needs for independent investigators to conduct rigorous observational studies examining exposures and factors associated with acute and late toxicities, cancer progression, recurrence, new malignancies and quality of life in OPC survivors.

participantsA total of 1811 patients with OPC with a minimum follow-up of 6 months have been consented to our prospective registry between 18 March 2015 and 29 December 2023. Clinical and treatment (Tx) data are available on all patients, including previously untreated patients (1443, 80%). Most previously untreated patients (97%) consented to longitudinal patient-reported outcomes and functional assessments for critical time points including pre-Tx, during-Tx and post-Tx at 3-6 months, 12 months, 18-24 months and annually up to 5 years. FINDINGS TO DATE: The median age for the MDA-OPC cohort is 66 years (range, 25-96) with the majority being male (89%), white (92%) and with human papillomavirus (HPV)/p16-associated OPC (88%) primarily located in the tongue base or tonsil (90%). For previously untreated patients, 79% were diagnosed with stage I/II disease, and nearly half underwent curative intent chemoradiation. Overall survival was significantly higher for HPV/p16-associated OPC at 1 year (98% vs 93%) and 5 years (83% vs 54%; p<0.0001) compared with HPV-negative disease. Longitudinal PRO and clinician-graded toxicity outcomes (eg, osteoradionecrosis, neuropathy, dysphagia) are summarised. FUTURE PLANS: Future work includes expansion of the MDA-OPC cohort and survivorship surveillance to 10 years under the recently funded OPC-SURVIVOR research programme (P01CA285249), which aims to identify non-invasive, clinic-ready biomarkers and examine novel phenotypes and mechanistically matched mitigation strategies for latent OPC sequelae. Additionally, we aim to expand our advanced data infrastructure by integrating large data streams from parallel clinical trials and imaging registries. TRIAL REGISTRATION NUMBERS: NCT01893307, NCT03145077.

Indexed as

Oropharyngeal NeoplasmsRegistriesAdultAgedAged, 80 and overClinical Trials, Phase III as TopicFemaleHumansLongitudinal StudiesMaleMiddle AgedMulticenter Studies as TopicPapillomavirus InfectionsPatient Reported Outcome MeasuresProspective StudiesQuality of LifeClinical ProtocolsHead & neck tumoursONCOLOGYPatient Reported Outcome Measures

Identifiers

PMID41290309
PMCPMC12645653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.